IMPACT OF COLORECTAL CANCER SCREENING IN THE FRAMEWORK OF UNIVERSAL HEALTH COVERAGE (UHC)
Author(s)
Pesci S1, Betelu MS2, Diaz C3
1Instituto Nacional del Cáncer, Ministerio de Salud, La Plata, B, Argentina, 2Dirección de Economía de la Salud, Ministerio de Salud, CABA, Argentina, 3Instituto Nacional del Cáncer, Ministerio de Salud, Caba, B, Argentina
OBJECTIVES Estimate the health impact and the economic costs of the implementation of screening for CRC with fecal occult blood test in the Argentine public health system METHODS Markov model that simulates the evolution in 50 years of a population cohort exposed to the risk of developing CRC in two analysis scenarios: “IFOBT screening” and “Non-existence of screening”. The natural history of the disease was simulated by ten health states based on information from scientific publications. The medical costs associated with the detection and treatment of polyps and cancer were estimated using public bidding prices from the Ministry of Health.The time horizon is 50 years and a 3% annual discount rate is used for costs and outcomes measured in QALYs. RESULTS According to our simulation, during the first five years of the screening implementation, an increase in the CRC incidence is observed. Reached the tenth year of implementation, the number of high-risk polyps and cases of CRC decrease by 40% and 50% respectively. In turn, the decrease in the risk of dying from CRC for people who participate in screening is 28%. Finally, the screening strategy with TiSOMF is an effective cost since the cost per AVAC of the intervention is USD 349 (incremental cost USD 120 and incremental AVAC 0.35), while the Argentine GDP per capita in dollars for the year 2018 was USD 11,645, that is, the RCEI is sufficiently lower than the national GDP per capita (0.03 GDP PC). CONCLUSIONS The implementation of screening with IFOBT is a cost effective intervention compared to the current situation.In the screening scenario, 90% of the expenditure is destined to the treatment of advanced CRC, while in the scenario with the same proportion, it is allocated to instances of prevention and early detection with an impact on hope and quality of life.
Conference/Value in Health Info
2020-05, ISPOR 2020, Orlando, FL, USA
Value in Health, Volume 23, Issue 5, S1 (May 2020)
Code
PCN166
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology